Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin
- PMID: 7053847
Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin
Abstract
The effect of free and DNA-linked daunorubicin on the colony-forming ability of granulocyte-macrophage committed stem cells and spleen colony-forming cells (i.e., multipotent stem cells) from normal mice has been studied in vitro and in vivo. After incubation of bone marrow cells in short-term suspension cultures, both committed and multipotent stem cells were more sensitive to the free drug than to the DNA complex, whereas the reverse was found in vivo after i.v. injection. However, when the in vitro cell-killing effect was related to the cellular retention of daunorubicin, no difference in activity was found between free and DNA-linked drug. Incubation of the bone marrow cells with a higher drug concentration for a shorter time resulted in a considerably lower cell survival than incubation with a lower concentration for a longer time, the intracellular exposure dose being the same. When the in vivo cell survival was related to the cellular retention of daunorubicin, the DNA complex was slightly more toxic than free drug, which can be explained by the higher peak concentration obtained. The results obtained with committed granulocytic stem cells and multipotent stem cells were comparable. Thus, the observed discrepancy between the in vitro and in vivo toxicity of free and DNA-linked daunorubicin can be explained by the differences in cellular retention of daunorubicin under these two conditions; i.e., the DNA complex probably acts as a slow-release preparation of daunorubicin. The results also demonstrated for the first time the importance of the peak concentration of daunorubicin in the target cells and indicate an important role of dose scheduling for the cytostatic effect of the drug.
Similar articles
-
Effects of daunorubicin and doxorubicin, free and associated with DNA, on hemopoietic stem cells.Cancer Res. 1979 Sep;39(9):3738-43. Cancer Res. 1979. PMID: 476697
-
Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention.Cancer Res. 1998 May 15;58(10):2141-8. Cancer Res. 1998. PMID: 9605758
-
NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.Toxic Rep Ser. 1999 Aug;(59):1-66, A1-E7. Toxic Rep Ser. 1999. PMID: 11803702
-
Characteristics of uptake and cytotoxicity of a low-density lipoprotein-daunomycin complex in P388 leukemic cells.Cancer Res. 1984 Aug;44(8):3377-82. Cancer Res. 1984. PMID: 6744272
-
Toxicology of daunorubicin in animals and man.Cancer Treat Rep. 1981;65 Suppl 4:9-18. Cancer Treat Rep. 1981. PMID: 6809317 Review.
Cited by
-
Sensitivity and resistance to chemotherapy in acute leukemia: correlation with in vitro drug uptake and lack of potentiation by verapamil.Med Oncol Tumor Pharmacother. 1987;4(1):17-21. doi: 10.1007/BF02934930. Med Oncol Tumor Pharmacother. 1987. PMID: 3600053
-
Uptake and metabolism of daunorubicin by human leukemia cells.Cancer Chemother Pharmacol. 1982 Dec;10(1):29-32. doi: 10.1007/BF00257233. Cancer Chemother Pharmacol. 1982. PMID: 6961971
-
Kinetics and sensitivity of daunorubicin in patients with acute leukemia.Cancer Chemother Pharmacol. 1984;13(3):230-4. doi: 10.1007/BF00269036. Cancer Chemother Pharmacol. 1984. PMID: 6488444
-
Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion.Cancer Chemother Pharmacol. 1987;20(4):311-5. doi: 10.1007/BF00262582. Cancer Chemother Pharmacol. 1987. PMID: 3690804
-
Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.Cancer Chemother Pharmacol. 1989;24(4):225-9. doi: 10.1007/BF00257622. Cancer Chemother Pharmacol. 1989. PMID: 2752502